Avenanthramide C
Based on 1 publication(s) in Google Scholar
Avenanthramide C is an orally active polyphenolic compound that penetrates the blood-brain barrier. Avenanthramide C is derived from oats. Avenanthramide C inhibits NF-κB nuclear translocation and inhibits the phosphorylation of PI3K, PLCγ1, Lyn, Syk, and Akt. Avenanthramide C inhibits the expression and activity of MMP-9 and inhibits MAPK phosphorylation. Avenanthramide C scavenges DPPH radicals, reduces intracellular ROS, and inhibits pro-inflammatory cytokine release and adhesion molecule expression. Avenanthramide C inhibits cell degranulation. Avenanthramide C attenuates active systemic anaphylaxis and inhibits passive cutaneous anaphylaxis. Avenanthramide C ameliorates PHZ-induced blood stasis. Avenanthramide C inhibits neuroinflammation, restores long-term potentiation, and improves recognition and spatial memory in Alzheimer's disease models. Avenanthramide C can be used for research on allergic inflammation, thrombosis, atherosclerosis, and Alzheimer's disease.
For research use only. We do not sell to patients.
- Purity : 99.13%
- CAS No.: 116764-15-9
- Formula: C16H13NO6
- Molecular Weight:315.28
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Avenanthramide C
MoreAll Phospholipase Isoforms
More
Biological Activity
Description
|
Lyn |
MMP-9 |
In Vitro
Avenanthramide C (0.01-100 µM; 12 h) is not cytotoxic up to 100 µM in RBL-2H3 cells[1].
Avenanthramide C (1-100 nM; 1 h) concentration-dependently inhibits β-hexosaminidase release in DNP-HSA-stimulated RBL-2H3 cells[1].
Avenanthramide C (1-100 nM; 1 h) concentration-dependently inhibits histamine release in DNP-HSA-stimulated RBL-2H3 cells[1].
Avenanthramide C (1-100 nM) suppresses DNP-HSA-stimulated intracellular calcium elevation in a concentration-dependent manner in RBL-2H3 cells[1].
Avenanthramide C (1-100 nM; 1 h) inhibits DNP-HSA-stimulated phosphorylation of PI3K and PLCγ1 in RBL-2H3 cells[1].
Avenanthramide C (1-100 nM; 1 h) concentration-dependently inhibits the gene expression and release of IL-4, IL-6, and TNF-α in DNP-HSA-stimulated RBL-2H3 cells[1].
Avenanthramide C (1-100 nM; 1 h) inhibits the phosphorylation of Lyn, Syk, and Akt and suppresses IκBα degradation and NF-κB nuclear translocation in DNP-HSA-stimulated RBL-2H3 cells[1].
Avenanthramide C (0-100 μM; 24 h) dose-dependently suppresses the TNF-α-induced increase in MMP-9 mRNA levels in HASMC cells[3].
Avenanthramide C (100 μM) inhibits the MAPK signaling pathway by decreasing phosphorylation of ERK, JNK, and p38, and reduces IκB phosphorylation in TNF-α-stimulated HASMC cells[3].
Avenanthramide C (50 μM; 2 h) restores impaired LTP in ex vivo hippocampal slices from 5XFAD mice[5].
Avenanthramide C (50 μM; 2 h) restores impaired LTP in ex vivo hippocampal slices from Tg2576 mice[5].
Avenanthramide C (1.0625-100 μg mL-1; 30 min) acts as a potent free radical scavenger in the cell-free DPPH assay with an IC50 of 7.38 μg mL-1[2].
Avenanthramide C (6.25-100 μg mL-1; 24 h) is non-toxic to HUVECs at concentrations up to 25 μg mL-1 but exhibits cytotoxic effects at 50 and 100 μg mL-1[2].
Avenanthramide C (6.25-25 μg mL-1; 24 h) dose-dependently attenuates intracellular ROS accumulation induced by t-BOOH in HUVECs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RBL-2H3 cells
-
Concentration:0.01-100 µM
-
Incubation Time:12 h
-
Result:Did not show any cytotoxicity up to 100 µM.
-
Cell Line:RBL-2H3 cells
-
Concentration:100 nM
-
Incubation Time:1 h (pre-treatment); 15 min (stimulation)
-
Result:Inhibited DNP-HSA-stimulated phosphorylation of PI3K and PLCγ1.
-
Cell Line:RBL-2H3 cells
-
Concentration:1-100 nM
-
Incubation Time:1 h (pre-treatment); 1 h (gene expression); 6 h (protein release)
-
Result:Inhibited the gene expression and release of pro-inflammatory cytokines (IL-4, IL-6, and TNF-α) in a concentration-dependent manner.
-
Cell Line:HUVECs
-
Concentration:0, 6.25, 12.5, 25, 50, and 100 μg mL-1
-
Incubation Time:24 h
-
Result:Showed no significant toxicity at concentrations below 25 μg mL-1.
At 50 and 100 μg mL-1, a marked reduction in cell viability was observed.
-
Cell Line:Human Aortic Smooth Muscle Cells (HASMC)
-
Concentration:0, 50, 100 μM
-
Incubation Time:24 h
-
Result:Dose-dependently suppressed the TNF-α-induced increase in MMP-9 mRNA levels in HASMC cells.
In Vivo
Avenanthramide C (0.1-10 mg/kg; p.o.; single dose; 1 h before DNP-HSA challenge) dose-dependently inhibits IgE-mediated passive cutaneous anaphylaxis[1].
Avenanthramide C (6 mg/kg; p.o.; daily; 2 weeks) rescues impaired long-term potentiation in 5XFAD Alzheimer's disease model mice[5].
Avenanthramide C (6 mg/kg; p.o.; daily; 2 weeks) rescues impaired long-term potentiation in Tg2576 Alzheimer's disease model mice[5].
Avenanthramide C (6 mg/kg; p.o.; once daily; 2 weeks) inhibits neuroinflammation in the hippocampus of 5XFAD and Tg2576 Alzheimer's disease model mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Imprinting Control Region (ICR) mice (male, 30-35 g, 6 weeks old)[1]
-
Dosage:0.1, 1, and 10 mg/kg
-
Administration:p.o.; on days 9, 11, and 13
-
Result:Dose-dependently increased the rectal temperature.
Reduced the serum histamine level.
Suppressed the increased serum levels of total IgE, OVA-specific IgE, and IL-4.
-
Animal Model:Imprinting Control Region (ICR) mice (male, 30-35 g, 6 weeks old)[1]
-
Dosage:0.1, 1, and 10 mg/kg
-
Administration:p.o.; single dose; 1 h before DNP-HSA challenge
-
Result:Decreased the PCA reaction (ear swelling and plasma extravasation) in a dose-dependent manner.
-
Animal Model:AB strain (2 days post-fertilization)[2]
-
Dosage:12.5, 25, 50 μg mL-1
-
Administration:in water; 24 hours
-
Result:Improved PHZ-induced blood stasis and reduced caudal vein thrombosis.
Enhanced cardiac red blood cell intensity.
Achieved antithrombotic ability of 6.7%, 25.4%, and 50.4% at 12.5, 25, and 50 μg mL-1, respectively.
-
Animal Model:C57BL/6J (male, 7-8 months old, wild-type); 5XFAD (male, 5-6 months old, transgenic)[5]
-
Dosage:6 mg/kg
-
Administration:p.o.; daily; 2 weeks
-
Result:Increased long-term potentiation in hippocampal slices.
Suppressed cleaved caspase-3 levels.
Increased p-GSK3β (Ser9) levels to levels comparable to wild-type controls.\nImproved object recognition memory with a preference index comparable to wild-type counterparts.
Significantly increased time spent in the target quadrant and increased number of platform crossings in the Morris water maze probe test.
-
Animal Model:C57BL/6J (male, 7-8 months old, wild-type); Tg2576 (male, 7-8 months old, transgenic)[5]
-
Dosage:6 mg/kg
-
Administration:p.o.; daily; 2 weeks
-
Result:Restored impaired long-term potentiation in hippocampal slices.
Restored GSK3β (Ser9) and caspase-3 active forms to basal levels.
-
Animal Model:C57BL/6J (male, wild-type); 5XFAD (male, 5-6 months old, transgenic); Tg2576 (male, 7-8 months old, transgenic)[5]
-
Dosage:6 mg/kg
-
Administration:p.o.; daily; 2 weeks
-
Result:Significantly reduced levels of activated microglia marker Iba1 in the hippocampus.
Significantly suppressed hippocampal levels of TNFα and IL-6.
Increased levels of IL-10.
Decreased phospho-forms of IKK and P65.
Chemical Information
-
CAS No. 116764-15-9
-
Appearance Solid
-
Molecular Weight 315.28
-
Formula C16H13NO6
-
Color Light yellow to brown
-
SMILES
O=C(C1=CC(O)=CC=C1NC(/C=C/C2=CC=C(C(O)=C2)O)=O)O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (158.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.93 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Protocol for Water Maze
The Morris Water Maze is a rodent spatial learning and memory assay in which a mouse or rat swims in opaque water to find an escape platform; in the hidden-platform version, the animal cannot see the platform and must use distal extra-maze cues to learn its fixed spatial location. The assay primarily measures hippocampus-dependent spatial learning during acquisition trials and spatial reference memory during probe trials after platform removal; readouts include escape latency, swim path length, swim speed, quadrant occupancy, platform-site crossings, and proximity to the former platform location.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
-
Data Sheet (297 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[4]. Matsukawa T, et al. Occurrence of avenanthramides and hydroxycinnamoyl-CoA:hydroxyanthranilate N-hydroxycinnamoyltransferase activity in oat seeds. Zeitschrift fur Naturforschung. C, Journal of biosciences. 2000;55(1-2):30-6. [Content Brief]
[5]. Ramasamy VS, et al. Avenanthramide-C Restores Impaired Plasticity and Cognition in Alzheimer's Disease Model Mice. Molecular neurobiology. 2020 Jan;57(1):315-330. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1718 mL | 15.8589 mL | 31.7178 mL | 79.2946 mL |
| 5 mM | 0.6344 mL | 3.1718 mL | 6.3436 mL | 15.8589 mL | |
| 10 mM | 0.3172 mL | 1.5859 mL | 3.1718 mL | 7.9295 mL | |
| 15 mM | 0.2115 mL | 1.0573 mL | 2.1145 mL | 5.2863 mL | |
| 20 mM | 0.1586 mL | 0.7929 mL | 1.5859 mL | 3.9647 mL | |
| 25 mM | 0.1269 mL | 0.6344 mL | 1.2687 mL | 3.1718 mL | |
| 30 mM | 0.1057 mL | 0.5286 mL | 1.0573 mL | 2.6432 mL | |
| 40 mM | 0.0793 mL | 0.3965 mL | 0.7929 mL | 1.9824 mL | |
| 50 mM | 0.0634 mL | 0.3172 mL | 0.6344 mL | 1.5859 mL | |
| 60 mM | 0.0529 mL | 0.2643 mL | 0.5286 mL | 1.3216 mL | |
| 80 mM | 0.0396 mL | 0.1982 mL | 0.3965 mL | 0.9912 mL | |
| 100 mM | 0.0317 mL | 0.1586 mL | 0.3172 mL | 0.7929 mL |